Champions Oncology (CSBR) Operating Income (2010 - 2026)
Champions Oncology (CSBR) posted quarterly Operating Income of -$522000.0 for Q2 2026, up 73.99% year-over-year from -$300015.5 in Q2 2025, and down 89.13% quarter-over-quarter from -$276000.0 in Q1 2026.
Champions Oncology (CSBR) Operating Income (2010 - 2026) Analysis & Trends
Champions Oncology's Operating Income history runs 17 years deep, the most recent figure standing at -$522000.0 for Q2 2026.
- In Q2 2026, Operating Income rose 73.99% year-over-year to -$522000.0; the TTM figure through Apr 2026 stood at -$1.1 million (down 125.04% YoY), while the FY2026 annual figure was -$1.1 million, down 125.04% from the prior year.
- Operating Income for Q2 2026 stood at -$522000.0, down from -$276000.0 in the prior quarter.
- The five-year high for Operating Income was $4.5 million in Q1 2025, with the low at -$2.6 million in Q1 2024.
- The 5-year median for Operating Income is -$297500.0 (2022), against an average of -$482166.7.
- The sharpest annual moves came in 2023 and 2025: Operating Income slumped 28028.57% in 2023, then surged 274.58% in 2025.
- Champions Oncology's Operating Income stood at $7000.0 in 2022, then plunged by 28028.57% to -$2.0 million in 2023, then soared by 137.44% to $732000.0 in 2024, then slumped by 74.73% to $185000.0 in 2025, then tumbled by 382.16% to -$522000.0 in 2026.
- Business Quant data shows CSBR's Operating Income at -$522000.0 in Q2 2026, -$276000.0 in Q1 2026, and $185000.0 in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 493.00 Mn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -815.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 325.05 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 231.44 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -1.55 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 133.12 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -375.75 Mn |
| 10 | Champions Oncology | 71.17 Mn | 71.17 Mn | 7.03 Mn | -522,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 30, 2026 | -522,000.00 |
| Jan 31, 2026 | -276,000.00 |
| Oct 31, 2025 | 185,000.00 |
| Jul 31, 2025 | -527,000.00 |
| Apr 30, 2025 | -2.01 Mn |
| Jan 31, 2025 | 4.50 Mn |
| Oct 31, 2024 | 732,000.00 |
| Jul 31, 2024 | 1.33 Mn |
| Apr 30, 2024 | -271,000.00 |
| Jan 31, 2024 | -2.58 Mn |
| Oct 31, 2023 | -1.96 Mn |
| Jul 31, 2023 | -2.55 Mn |
| Apr 30, 2023 | -2.52 Mn |
| Jan 31, 2023 | -2.46 Mn |
| Oct 31, 2022 | 7,000.00 |
| Jul 31, 2022 | -284,000.00 |
| Apr 30, 2022 | -311,000.00 |
| Jan 31, 2022 | 830,000.00 |
| Oct 31, 2021 | 263,000.00 |
| Jul 31, 2021 | -175,000.00 |